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Abstract
Background: Prostate cancer remains the most common cancer in men. Qualitative or semi-quantitative
immunochromatographic measurements of prostate specific antigen (PSA) have been shown to be simple,
noninvasive and feasible. The aim of this study was to evaluate an optimized gold immunochromatographic
strip device for the detection of PSA, in which the results can be analysed using a Chromogenic Rapid Test
Reader to quantitatively assess the test results.
Methods: This reader measures the reflectance of the signal line via a charge-coupled device camera. For
quantitative analysis, PSA concentration was computed via a calibration equation. Capillary blood samples from
305 men were evaluated, and two independent observers interpreted the test results after 12 min. Blood samples
were also collected and tested with a conventional quantitative assay.
Results: Sensitivity, specificity, positive and negative predictive values, and accuracy of the PSA rapid quantitative test
system were 100, 96.6, 89.5, 100, and 97.4 %, respectively. Reproducibility of the test was 99.2, and interobserver
variation was 8 % with a false positive rate of 3.4 %. The correlation coefficient between the ordinary quantitative
assay and the rapid quantitative test was 0.960.
Conclusions: The PSA rapid quantitative test system provided results quickly and was easy to use, so that tests
using this system can be easily performed at outpatient clinics or elsewhere. This system may also be useful for
initial cancer screening and for point-of-care testing, because results can be obtained within 12 min and at a cost
lower than that of conventional quantitative assays.
Keywords: Prostate specific antigen, Prostate cancer, Chromogenic rapid test reader, Gold
immunochromatographic strip
Background
Measuring prostate specific antigen (PSA) levels is widely
used to identify men with an increased risk of prostate
cancer. The serum- or plasma-based immunoassays cur-
rently available are associated with time consuming sample
processing and the need for sophisticated technical equip-
ment. Therefore, various strip tests for the qualitative and
semi-quantitative determination of PSA based on immu-
nochromatographic measurements of serum [1–7] or
whole blood [8] have been developed.
Visual assessment of the currently available whole
blood assays allows for a yes or no decision without def-
inite information regarding the concentration of PSA in
the blood. Although this kind of qualitative assay is suffi-
cient for clinical decision making, prognostic informa-
tion inherent to the concentration of circulating PSA is
lost. Furthermore, inter-individual variability of visual
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assessment of the test strip at the detection limit of the
assay may cause lead to substantial analytical errors [9].
In this study, we evaluated an improved assay for PSA
and a newly developed reader to overcome the limita-
tions of previous tests and to enable reliable quantitative
and rapid testing for PSA. This tool may be useful for
initial cancer screening and may be applied in point-of-
care testing.
Methods
Patients and serum samples
From June 2014 to May 2015, 305 male patients (mean
age 67 years, range 40–98 years), with or without pros-
tate disease were analysed. All of the men were evalu-
ated at E-Da Hospital in Taiwan.
Control method
For comparative purposes, a blood sample from each
patient was collected immediately before the test for use
in the standard laboratory method, a chemiluminescent
microparticle immunoassay (CMIA), to determine the
concentration of PSA. The blood samples were allowed
to clot for 1 h at room temperature before being centri-
fuged. The sera were then immediately analysed using
an ABBOTT ARCHITECT i System analyzer PSA assay
according to the manufacturer’s instructions. The study
protocol was approved by the Human Research Ethics
Committee of the E-Da hospital, and written informed
consent was obtained from each participant before
enrolment.
Principles of the PSA rapid quantitative test system
The PSA rapid quantitative test system includes a spe-
cial cassette (C.J. Biotec Corp. Pingtung, Taiwan) and a
Chromogenic Test Reader (KAIWOOD Technology
Co. Ltd., Tainan, Taiwan). The special cassette consists
of two different regions: the sample well and the test
area. The PSA test strip included the sample pad, con-
jugated pad, nitrocellulose membrane, absorption pad,
and a backing card. The anti-PSA antibody and goat
anti-mouse immunoglobulin G antibody defined as the
test line and control line were immobilized on the nitro-
cellulose membrane. The anti-PSA antibody-colloidal gold
conjugates were immobilized on the conjugated pad,
which was defined as the mixture area. After the sample
solution including the PSA antigen in the serum was
dropped into the sample pad, the PSA antigen first
bonded with the anti-PSA antibody-colloidal gold conju-
gates and then bonded with the anti-PSA antibody. When
the PSA concentration was increased, larger volumes of
the colloid gold were aggregated in the test line and this
deepens the color of the test line. In addition, excess la-
beled antibody conjugate will be captured at control line
and a second red colored line was also observed of the
membrane, indicating the proper test performance. The
colored band must be visualized on the control line, so
the test could be considered as invalid if there is no color
line present in the control region.
The Chromogenic Test Reader mainly consists of an
Advanced RISC Machine (ARM) processors, a comple-
mentary metal-oxide semiconductor (CMOS) sensor car-
rier, a set of LED lights, and a test strip carrier. The
control and test lines of the PSA strip are captured by
the Chromogenic Test Reader (Fig. 1). The test and con-
trol lines in the detection zone are recognized by an
evaluation algorithm. The intensity of the test line, de-
termined by measuring its reflectance, is directly propor-
tional to the concentration of PSA. The top image in
Fig. 2 shows the gold immunochromatographic assay
(GICA) strip with PSA concentrations of 20 ng/mL and
60 ng/mL. The bottom image shows the corresponding
curve of the GICA strip signal corresponding. The left
peak of the strip is the test line, and the other is the con-
trol lines. The figure shows that the higher the PSA con-
centration the higher the peak of the test line. The
acquired digital signal after pre-filtering was then proc-
essed by the ARM processors. In order to quantitatively
analyse the GICA strip, the curve of the strip signal was
first segment using the fuzzy C-means algorithm [10,
11] to obtain the location of the test line and control
line. In addition, to establish a standard calibration curve
for the Chromogenic Test Reader, we used serum sam-
ples with various PSA concentrations (60, 30, 20, 15, 10,
7.5, 3.25, 1 ng/mL) were injected into the PSA test strip.
The serum samples were prepared by the high PSA con-
centration (60 ng/mL) of the antigen. The color intensity
of test line analyzed by Chromogenic Test Reader was con-
verted via the standard calibration curve and interpolation
method into a PSA concentration.
Test procedure
The PSA test cassette is provided with droppers and a buf-
fer solution. The patient’s fingertip should be swabbed
with alcohol and then allowed to dry for 30 s. The
fingertip is then pricked with a sterile lancet to obtain
one drop of blood, and the droppers are used to draw
the blood sample and then transfer it to the sample well
on the PSA cassette. After 2 min, two drops of a buffer
solution are added to the sample well to allow the
blood to migrate. If visible migration across the test
area does not start, an additional drop of buffer solu-
tion can be added to the sample well. When PSA con-
centration levels are ≥ 4 ng/mL, a burgundy-coloured
band should develop on the test line. For quantitative
analysis and to reduce errors, the Chromogenic Test
Reader is used to measure the colour signals of the test
line, as shown in Fig. 1. Interpretation of the test must
be done after 10 min.
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Fig. 1 The control line and test line of the prostate specific antigen (PSA) strip were captured by the Chromogenic Rapid Test Reader
Fig. 2 The image of gold immunochromatographic assay (GICA) strip and the curve of the GICA strip signal
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Evaluation procedure
Two urologists who were unaware of the measured PSA
values interpreted the tests independently from one an-
other to avoid bias. The observers were also unaware
that the two different tests were being performed on the
same patients to avoid bias. Positive and negative results
of each test were classified as true positive or negative
and false negative or positive by comparing them with
the quantitative PSA results as measured by the AB-
BOTT ARCHITECT i System analyzer PSA assay, using
the threshold value of 4 ng/ml.
Statistical analysis
All statistical analyses were performed using the Statis-
tical Package for Social Science (SPSS for Windows, ver-
sion 10.0; SPSS Inc., Chicago, Ill). Sensitivity, specificity,
accuracy, positive and negative predictive values of the
quantitative PSA test was calculated. Sensitivity was de-
fined as the ratio between the true positive results and
the sum of the true positive and false negative results.
Specificity was defined as the ratio between the true
negative results and the sum of the true negative and
false positive results. The positive predictive value was
defined as the ratio between the true positive results and
the sum of all positive results, and the negative predict-
ive value was defined as the ratio between the true nega-
tive results and the sum of all negative results. Accuracy
was defined as the ratio between the sum of the true ob-
servations (positive and negative) and the total observa-
tions. Relationships between GICA method and CMIA
method were examined using Pearson’s correlation
analyses.
Results
The patients were divided into two groups on the basis
of the conventional quantitative PSA value. Of the 305
patients, 229 (75.1 %) had a PSA value of < 4 ng/mL
(median 0.79 ng/mL; range 0.05-3.98 ng/mL) and 76
(25 %) had a PSA value of > 4 ng/mL (median 7.59 ng/
mL; range 4.01-169.10 ng/mL). When the patients were
divided into two groups on the basis of the rapid quantita-
tive PSA value, of the 305 patients, 221 (72.5) had a PSA
value of < 4 ng/mL (median 1.03 ng/mL; range 0.40-
4.07 ng/mL) and 84 (27.5 %) had a PSA value of > 4 ng/mL
(median 6.33 ng/mL; range 4.10-112.11 ng/mL).
The within-run imprecision experiments (n = 9) with
the PSA rapid assay yielded CVs between 4.4 and 13.1 %
for PSA concentrations between 1.12 and 12.39 ng/mL.
The CV for day-to-day imprecision, performed as 9 re-
petitive measurements on 9 subsequent days, was be-
tween 6.6 and 7.3 % (Table 1).
The positive and negative results obtained by the two
methods are shown in Table 2. In the table, (tp) indicates
that both methods classified the test sample as positive;
(tn) indicates that both methods classified the test sam-
ple as negative; (fn) indicates that the CMIA method
classified the test sample as positive but the GICA
method classified the test sample as negative; and (fp)
indicates that the CMIA method classified the test
sample as negative but the GICA method classified the
test sample as positive. Sensitivity, specificity, positive
and negative predictive values, and accuracy of the
PSA rapid quantitative test system were 100 %, 96.6 %,
89.5 %, 100 %, and 97.4 %, respectively. The GICA
method had a false positive rate of 3.4 and a false nega-
tive rate of 0 % compared to the CMIA method. There
was a high level of reproducibility of the GICA test
(99.2 %), with an overall concordance rate between the
observers of 98 %. The correlation coefficient between
the two methods was 0.960 (Fig. 3). In addition, the re-
sults of the PSA rapid quantitative test are comparable
with those of other PSA one-step tests described in the
literature, using serum or capillary blood (Table 3).
Discussion
In this study, we introduce a rapid quantitative deter-
mination method to measure the concentration of PSA
using a GICA strip based on the Chromogenic Rapid
Test Reader. Comparing the GICA method and the
CMIA method revealed a strong correlation coefficient






















Results of the CMIA method (gold standard)
Positive Negative Total
Positive 68 (tp) 8 (fp) 76
Negative 0 (fn) 229 (tn) 229
Total 68 237 305
GICA gold immunochromatographic assay, CMIA chemiluminescent
microparticle immunoassay
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of 0.960 between these two methods. The results suggest
that the GICA method may be applicable to quantita-
tively determine PSA concentrations.
The incidence rate of prostate cancer has increased
remarkably. Since radical therapeutic methods are still
limited, the early detection and treatment of prostate
cancer is essential. Although screening for prostate can-
cer is still one of the most controversial issue in oncol-
ogy, it is well recognized that a combination of a digital
rectal examination or ultrasonography and a PSA test is
the most useful and effective method to diagnose pros-
tatic carcinoma [12–15].
Previously, the widespread use of PSA testing has been
reported to be one of the factors that have led to a sig-
nificant increase in the diagnosis of organ-confined tu-
mours and a decline in prostate cancer mortality rates
[16–19]. Furthermore, evaluation of serum PSA level at
45 years of salvage radiotherapy for biochemical relapses
after prostatectomy may serve as a significant prognosti-
cator for both biochemical and clinical disease-free out-
comes [20]. McLeod DG suggested that PSA testing
remains the most efficacious marker available, both to
evaluate therapy and to use as a screening tool [21]. In
the present study, we introduce an optical inspection
system to measure PSA concentrations and a new detec-
tion model covering from qualitative to quantitative ana-
lysis. Of note, this system is very easy to use and it only
needs an initial and brief training to interpret the test re-
sults correctly. In addition, it would be useful in the set-
ting of both general practitioner and office urologist.
Furthermore, it uses whole blood from a finger prick
(30 μl) which is more patient-friendly than traditional
venepuncture. In addition, other rapid PSA tests have
been reported to require serum samples or capillary
whole blood (approximately 80 μl) [1, 6, 22]. Using fin-
ger prick whole blood rather than a serum sample saves
time (a standard laboratory process to obtain serum
needs 1 h to allow for blood clotting after collection,
and 10–15 min to separate serum from blood by centri-
fugation) and produces the final screening results in
about 12 min. Another benefit of the PSA rapid quanti-
tative test system is that the cost is significantly lower
compared to a conventional quantitative serum PSA test
in Taiwan, (about New Taiwan (NT) $300 vs. NT$400).
Considering the number of people that could be
Fig. 3 Comparison of prostate specific antigen (PSA) concentrations
(ng/mL) obtained with the gold immunochromatographic assay
(GICA) and quantitative standard laboratory method (chemiluminescent
microparticle immunoassay, CMIA)
Table 3 Performance of various PSA one-step tests reported in the literature
Author PSA test Sample Time Sensitivity Specificity
Dok An et al [1] One Step PSATM Serum 15 min 100 90
Jung et al [3] Chembio Serum 10 min 67 87
Jung et al. [3] Medpro Serum 10 min 87 88
Jung et al. [3] Syntron Serum 10 min 93 93
Jung et al. [3] Seratec Serum 10 min 80 97
Lein et al. [4] Tandem-E Serum 12 min 63 92
Lein et al. [4] lMx Serum 12 min 68 95
Lein et al. [4] LIA-mat Serum 12 min 83 87
Madersbacher et al. [6] Oncoscreen® Serum 10 min 93 93
Berg et al. [8] One-Step PSA Serum 10 min 90.5 83.8
Fernández-Sánchez et al. [24] CanAg Serum 20 min 87 79
Fernández-Sánchez et al. [24] Immulite Serum 20 min 77 83
Berg et al. [8] Urale® Capillary whole blood 12 min 91 81
Miano et al. [23] One-Step PSA Capillary whole blood 20 min 97.6 90.4
Wu et al. Quantitative Capillary whole blood 12 min 100 96.6
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involved in a screening programme for prostate cancer,
the savings could be. Given the intended use of this test
(initial prostate cancer screening programme), sensitivity
is more important than specificity. The PSA rapid quan-
titative test system had a very high sensitivity (100 %),
even near the cut-off value of PSA of 4 ng/ml. While the
overall specificity was 96.6 %, the false-positive rate was
3.4 % with a PSA concentration in the range of 3–4 ng/
ml. The accuracy was also very high (97.4 %). The re-
sults of the PSA rapid quantitative test are comparable
with those of other PSA one-step tests described in the
literature [1, 3, 4, 6, 8, 23,24], using serum or capillary
blood (Table 3). Another advantage of the PSA rapid
quantitative test is that the reader can be linked and
send results directly to a hospital’s or healthcare centre’s
data management system. As a result, it is now possible
to measure highly specific and sensitive results of PSA
concentration within 12 min without the need for a so-
phisticated clinical chemistry environment.
A previous study suggested that a semi-quantitative
immunochromatographic test was difficult to perform
and that interpretation was difficult. Furthermore, the
rate of false strip test results was disappointing even for
PSA values far from the cut-off value [25]. Various rea-
sons, apart from the possible technical inferiority of the
investigated product, may explain this finding. First, the
colour stability of the test is particularly affected by varia-
tions in the reading time [3]. Second, the testing of whole
blood instead of serum may be associated with less advan-
tageous immunochromatographic properties. Third, well-
known differences in the PSA methods [5, 26, 27] used for
comparisons may influence the results such as: (1) Anti-
bodies; affinity and specificity for various epitopes of PSA
forms [28–30] or cross-reactivity to PSA homologous an-
tigens [31]. (2) Calibration of the assay method. (3) Pro-
cedure of the assay; incubation time, equilibrium or
kinetics [28, 32], adjuvants (e.g. stabilizing standard prepa-
rations, particularly albumin), “high-dose hook” effect. (4)
Lot-to-Lot variations in assays [33]. (5) Interference; auto-
anti-PSA- antibodies. Fourth, handling and interpretation
of the strip tests was mostly performed by trained investi-
gators in other studies. Ultimately, the performance of the
test is highly dependent on the study population, particu-
larly with regards to the distribution of PSA values and
the prevalence and extent of PSA concentrations exceed-
ing the cut-off value [25]. In the present study, the PSA
rapid quantitative test had a higher sensitivity and specifi-
city compared with previous studies [1, 3, 4, 6, 8, 22–24],
which may be because the results were interpreted using
technical signal detectors and a user with experience in
handling and interpreting such detectors, which may
overcome the problem that strip test are frequently dif-
ficult to read, since the colour reaction in the test field
can be weak.
The main limitation of this test is that eight samples
with values of less than 4 ng/mL showed false positive
results in the range 3–4 ng/ml where the possibility of
prostate cancer detection is still about 25 % [34]. The
most important and most concerning cause of an ele-
vated PSA is prostate cancer. However, prostate cancer
is only one of many potential causes of an elevated
PSA. Virtually anything that irritates the prostate will
cause the PSA to rise, at least temporarily. The most com-
mon cause of PSA elevation includes benign prostatic
hyperplasia (enlargement of the prostate, secondary to a
noncancerous proliferation of prostate gland cells) and
prostatitis (inflammation of the prostate). In fact, PSA ele-
vation can also occur with prostate manipulation such as
ejaculation, prostate examination, urinary retention or
catheter placement, and prostate biopsy. Hence, elevated
the specificity for this PSA rapid quantitative test system,
ranging between 2 and 4 ng/mL, is need. Moreover, previ-
ous study indicated that the use of free/total PSA ratio in
patients with PSA levels of 4–10 ng/mL should enhance
the specificity of PSA screening and decrease the number
of unnecessary biopsies [35]. However, a free/total ratio is
not available with this method. We will test more samples
in the near future to further examine the suitability of
such kits for mass screening.
Conclusions
The results of this study showed that this PSA rapid
quantitative test with a GICA strip based on a Chromo-
genic Rapid Test Reader yielded good results and was
appropriate for the quantitative determination of PSA
concentration. We do not believe that a PSA rapid quan-
titative test and clinical chemistry tests are mutually ex-
clusive methods. Clearly laboratory-based methods have
a better analytical performance [36]. Thus, if time is not
critical and the appropriate equipment is available,
laboratory-based methods may still be preferable. How-
ever, for many clinical situations and for many point-of-
care measurements, PSA rapid quantitative testing may
be the preferred method, particularly when the results
can be sent directly to a hospital data management sys-
tem as is possible with the PSA Chromogenic Reader.
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